Navigation Links
Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting

BOSTON--(BUSINESS WIRE)--May 2, 2007 - Acorda Therapeutics, Inc.(R) (Nasdaq: ACOR) today presented data from a Phase 3 clinical trial of Fampridine-SR in people with multiple sclerosis (MS) at the American Academy of Neurology meeting. Andrew Goodman, M.D., Director of the Multiple Sclerosis Center at the University of Rochester, presented top-line results on walking ability, leg strength, spasticity and clinician and subject global impressions. Dr. Goodman also presented a review of safety data.

Presentation Highlights

The prospectively-designed analysis plan for the study was based on a responder criterion, defined as a consistent improvement in walking speed, as measured with the Timed 25 Foot Walk. A significantly greater proportion of people taking Fampridine-SR were Timed Walk Responders compared to people taking placebo (34.8 percent vs. 8.3 percent, p less than 0.0001). Increased response rate with treatment was seen across all four major (relapsing and progressive) types of MS.

The mean increase in walking speed, compared to pre-treatment, for Fampridine-SR treated Timed Walk Responders was significantly greater at every visit during the treatment period, compared to both Fampridine-SR Timed Walk Non-Responders and placebo treated patients (p less than 0.0001). The average increase in walking speed over the treatment period, compared to baseline, was 25.2 percent for the drug treated Timed Walk Responders vs. 4.7 percent for the placebo group. In follow-up visits, at two and four weeks after the end of the treatment period, Responder and Non-responder groups returned to their baseline walking speeds.

The clinical significance of the consistent response on the timed walk was validated in the trial primarily by the 12-Item Multiple Sclerosis Walking Scale (MSWS-12), a patient self-assessment of walking disability. There was a statistically significant improvement in the MSWS-12 score
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Acorda Therapeutics Presents Fampridine-SR Data at ACTRIMS Meeting
2. Acorda Therapeutics to Host Analyst and Investor Reception
3. Acorda Therapeutics Presentation of Fampridine-SR Phase 3 Data Selected for Scientific Highlights Program at the American Academy of Neurology Meeting
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
6. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
7. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
8. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
9. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
10. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
11. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
Post Your Comments:
(Date:7/13/2014)... -- Eli Lilly and Company (NYSE: LLY ... in genetically engineered mice examining combination therapy with ... and beta-secretase inhibitor BACE (LY2811376). Data results found ... clumps of amyloid-beta protein in the brain – ... Alzheimer,s disease (AD) – than use of one ...
(Date:7/11/2014)... , July 11, 2014  Rock Creek Pharmaceuticals, Inc. ... today announced that the Food and Drug Administration ("FDA"), ... comments on RCP,s Investigational New Drug ("IND") application before ... in the US. Dr. Chris Chapman ... and comments on our IND. When we receive the ...
(Date:7/11/2014)... 2014  Kindred Hospital Houston Northwest, with Wound ... of its new outpatient wound healing center.  The ... with chronic, hard to heal wounds. Chronic wounds ... amputation, lower leg wounds related to blood flow ... traumatic injury wounds which are complex and demonstrate ...
Breaking Medicine Technology:New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 2New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 3Rock Creek Pharmaceuticals Issues Update On US Investigational New Drug Application 2Kindred Hospital Houston Northwest, With Wound Care Specialists, Opens Outpatient Wound Healing And Hyperbaric Center 2
... The board of directors of Hospira, Inc. (NYSE: ... today announced that Christopher B. Begley, chairman and chief executive ... CEO position after more than six years of dedicated service. ... He will then remain an employee of the company as ...
... Amsterdam Next April 2011 -- AMSTERDAM, August 20, 2010 ... ... var shortURL = ... so we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; ...
Cached Medicine Technology:Hospira Announces CEO Succession Plan 2Hospira Announces CEO Succession Plan 3Hospira Announces CEO Succession Plan 4Pharma and Food Thought Leaders Set to Converge in Amsterdam Next April 2011 2Pharma and Food Thought Leaders Set to Converge in Amsterdam Next April 2011 3Pharma and Food Thought Leaders Set to Converge in Amsterdam Next April 2011 4Pharma and Food Thought Leaders Set to Converge in Amsterdam Next April 2011 5Pharma and Food Thought Leaders Set to Converge in Amsterdam Next April 2011 6
(Date:7/13/2014)... (PRWEB) July 13, 2014 Manchester United ... with the 2014 Guinness International Champions Cup. The 2014 ... soil each year because of the talent of it brings ... and AS Roma will compete in the 2014 event spread ... July 24 with a game between Olympiacos and Milan and ...
(Date:7/13/2014)... An editorial published today in The Lancet ... into consideration the long term neurological problems that ... the most common form of sports-related traumatic brain ... concussions may include dementia, amyotrophic lateral sclerosis, and ... what is perhaps more concerning, is that even ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 Intraocular Lens ... and Forecast 2013 - 2019 , Intraocular lens (IOL) ... from myopia or cataracts. The lenses are inserted inside ... cataract surgery intraocular lens replaces the focusing power of ... original crystalline lens to deliver the light focusing function ...
(Date:7/13/2014)... Recently, MillionaireCasket.com, a well-known casket manufacturer from China, has announced ... company’s chief executive officer has announced a new promotion for ... at discounted prices, from 15 to 26 percent off. , ... huge demand in the current market. We are excited to ... lot of high quality products for sale. Many of our ...
(Date:7/13/2014)... July 13, 2014 The report ... Molybdenum, Iron), Form (Chelated & Non Chelated), Application ... - Global Trends and Forecast to 2018” defines ... an analysis and forecasting of the global value ... the driving and restraining factors for the global ...
Breaking Medicine News(10 mins):Health News:Manchester United vs. AS Roma Tickets in Denver, CO at Sports Authority Field at Mile High: Ticket Down Slashes Ticket Prices on International Champions Cup in Denver 2Health News:Manchester United vs. AS Roma Tickets in Denver, CO at Sports Authority Field at Mile High: Ticket Down Slashes Ticket Prices on International Champions Cup in Denver 3Health News:Intraocular Lens (IOL) Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 2Health News:Intraocular Lens (IOL) Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 3Health News:Intraocular Lens (IOL) Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 4Health News:Cheap Oak Caskets Recently Unveiled By China Casket Manufacturer MillionaireCasket.com 2Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 2Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 3Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 4
... Specialties, Mfg. is pleased to announce the introduction of push-to-connect ... Mfg and designed with John Guest push-to-connect style fittings integrated ... offers versatility and customization for a variety of applications. ... ...
... Oct. 7 ProGenTech Limited, a life,sciences & ... CA,has signed a licensing agreement with Human Genetic ... gain access to key,hospital-acquired infection targets, payment terms ... the agreement, Human Genetic Signatures will develop,assays for ...
... for food-allergic kids and their parents. All kids want to join in ... they can…as long as they steer clear of the foods that pose ... ... EON) October 6, 2008 -- Enjoy Life Foods, the country,s leader ...
... VOLC ), a leader in the development, ... treatment of coronary and peripheral artery,disease, today announced ... Rancho Cordova to San Diego. The new corporate,headquarters ... San Diego and now,houses corporate executives, marketing, finance, ...
... The United States has,intervened in a lawsuit ... claims to Medicare arising from illegal kickbacks ... (DME) suppliers, the,Justice Department announced today. The ... (MediNet), GGNSC Holdings LLC,Golden Gate Ancillary LLC, ...
... presented at the American College of Gastroenterology Annual ... TAK-390MR resulted in higher healing rates than lansoprazole ... esophagitis (EE). TAK-390MR combines dexlansoprazole with a Dual ... separate releases of drug for extended duration of ...
Cached Medicine News:Health News:ProGenTech Targets Clinical Diagnostics and Applied Sciences Markets with Human Genetic Signatures Deal 2Health News:ProGenTech Targets Clinical Diagnostics and Applied Sciences Markets with Human Genetic Signatures Deal 3Health News: Enjoy Life Foods Teams with AllergyMoms.com to Ensure Halloween Isn't 'Tricky' for Food-Allergic Kids and Families : Provides tips for being allergy-aware this Halloween 2Health News: Enjoy Life Foods Teams with AllergyMoms.com to Ensure Halloween Isn't 'Tricky' for Food-Allergic Kids and Families : Provides tips for being allergy-aware this Halloween 3Health News: Enjoy Life Foods Teams with AllergyMoms.com to Ensure Halloween Isn't 'Tricky' for Food-Allergic Kids and Families : Provides tips for being allergy-aware this Halloween 4Health News:Volcano Corporation Announces the Relocation of Corporate Headquarters to San Diego 2Health News:Volcano Corporation Announces the Relocation of Corporate Headquarters to San Diego 3Health News:Volcano Corporation Announces the Relocation of Corporate Headquarters to San Diego 4Health News:U.S. Intervenes in False Claims Act Suit Against McKesson Corp. and Golden Horizons Nursing Homes 2Health News:Takeda's investigational PPI TAK-390MR demonstrated higher healing rates compared to lansoprazole 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: